Nicotine addiction through a neurogenomic prism: Ethics, public health, and smoking

Nicotine and Tobacco Research

Volumn 7, Issue 2, 2005, Pages 181-197

  Caron, Lorraine ^a   Karkazis, Katrina ^b   Raffin, Thomas A ^b   Swan, Gary ^c   Koenig, Barbara A ^b  

^a Gouvernement du Quebec   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; METHOXSALEN; NEUROTRANSMITTER; NICOTINE; NORTRIPTYLINE; TRANYLCYPROMINE; VIGABATRIN;

BRAIN DISEASE; CIGARETTE SMOKING; DRUG METABOLISM; ETHICS; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEALTH BEHAVIOR; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH PROMOTION; HEREDITY; HUMAN; INDIVIDUALIZATION; LIFESTYLE; MOLECULAR GENETICS; NEUROBIOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SMOKING CESSATION; SMOKING HABIT; TOBACCO DEPENDENCE;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION;

BEHAVIOR, ADDICTIVE; ETHICS, RESEARCH; HUMANS; NEUROSCIENCES; NICOTINE; PHARMACOGENETICS; PRIMARY PREVENTION; PUBLIC POLICY; RESEARCH DESIGN; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 20344408144     PISSN: 14622203     EISSN: None     Source Type: Journal    
DOI: 10.1080/14622200500055251     Document Type: Review

References (225)

1. Allmark, P. (1995). Smoking and health: Is discrimination fair? Professional Nurse, 10, 811-813.
2. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
3. Anderson, V. E. (1994). Genes, behavior, and responsibility: Research perspectives. In M. S. Frankel & A. H. Teich (Eds.), The genetic frontier: Ethics, law, and policy (pp. 105-130). Washington, DC: American Association for the Advancement of Science.
4. Anonymous. (2001). 1st Conference on reward deficiency syndrome: Genetic antecedents and clinical pathways. Molecular Psychiatry, 6 (1 Suppl. 1), S1-S8.
5. Audrain, J., Boyd, N. R., Roth, J., Main, D., Caporaso, N., & Lerman, C. (1997). Genetic susceptibility testing in smoking-cessation treatment: One-year outcomes of a randomized trial. Addictive Behaviors, 22, 741-751.
6. Bailey, R. C. (1997). Hereditarian scientific fallacies. Genetica, 99, 125-133.
7. Baird, P. (1990). Genetics and health care: A paradigm shift. Perspective in Biology and Medicine, 33, 203-213.
8. Bell, J. (1998). The new genetics and clinical practice. British Medical Journal, 316, 618-620.
9. Benowitz, N. L. (1999). Nicotine addiction. Primary Care, 26, 611-631.
10. Ben-Yehuda, N. (1990). The politics and morality of deviance: Moral panics, drug abuse, deviant science, and reverse stigmatization. Albany: State University of New York Press.
11. Bergen, A. W., Korczak, J. F., Weissbecker, K. A., & Goldstein, A. M. (1999). A genome-wide search for loci contributing to smoking and alcoholism. Genetic Epidemiology, 17, S55-S60.
12. Bierut, L. J., Dinwiddie, S. H., Begleiter, H., Crowe, R. R., Hesselbrock, V., Nurnberger, J. I., Jr., Porjesz, B., Schuckit, M. A., & Reich, T. (1998). Familial transmission of substance dependence: Alcohol, marijuana, cocaine, and habitual smoking. A report from the Collaborative Study on the Genetics of Alcoholism. Archives of General Psychiatry, 55, 982-988.
13. Bierut, L. J., Rice, J. P., Edenberg, H. J., Goate, A., Foroud, T., Cloninger, C. R., Begleiter, H., Conneally, P. M., Crowe, R. R., Hesselbrock, V., Li, T. K., Nurnberger, J. L, Jr., Porjesz, B., Schuckit, M. A., & Reich, T. (2000). Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. American Journal ot Medical Genetics, 90, 299-302.
14. Blank, R. H. (1999). Brain policy: How the new neuroscience will change our lives and our politics. Washington. DC: Georgetown University Press.
15. Blum, K., Braverman, E. R., Holder, J. M., Lubar, J. F., Monastra, V. J., Miller, D., Lubar, J. O., Chen, T. J., & Comings, D. E. (2000). Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. Journal of Psychoactive Drugs, 32 (Suppl i-iv), 1-112.
16. Blum, K., Noble, E. P., Sheridan, P. J., Montgomery, A., Ritchie, T., Jagadeeswaran, P., Nogami, H., Briggs, A. H., & Cohn, J. B. (1990). Allelic association of human dopamine D2 receptor gene in alcoholism. The Journal of the American Medical Association, 263, 2055-2060.
17. Botkin, J. R., McMahon, W. M., & Francis, L. P. (Eds.). (1999). Genetics and criminality: The potential misuse of scientific information in court. Washington, DC: American Psychological Association.
18. Boyle, P. J. (1992). Introduction: Genetic grammar, health, illness, and the Human Genome Project. Special supplement. Hastings Center Report, 22 (4), S1.
19. Brown, C. (2000, August). "Judge me all you want": Cigarette smoking and the stigmatization of smoking. Paper presented at the annual meeting of the Society for the Study of Social Problems, Washington, DC.
20. Buchanan, A., Brock, D. W., Daniels, N., & Wikler, D. (Eds.). (2001). From chance to choice: Genetics and justice. Cambridge, England: Cambridge University Press.
21. Byars, C. (1998, March 4). Study: Smoking may be tied to heredity; Researchers say genes play a role in addiction. The Houston Chronicle, A-17.
22. Callahan, D., & Jennings, B. (2002). Ethics and public health: Forging a strong relationship. American Journal of Public Health, 92, 169-176.
23. Callahan, D., Koenig, B., & Minkler, M. (2000). Promoting health and preventing disease: Ethical demands and social challenges. In D. Callahan (Ed.), Promoting healthy behavior: How much freedom? Whose responsibility? (pp. 153-170). Washington, DC: Georgetown University Press.
24. Caporaso, N. E., Lerman, C., Audrain, J., Boyd, N. R., Main, D., Issaq, H. J., Ultermahlan, B., Falk, R. T., & Shields, P. (2001). Nicotine metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiology, Biomarkers & Prevention, 10, 261-263.
25. Caraballo, R. S., Giovino, G. A., Pechacek, T. F., Mowery, P. D., Richter, P. A., Strauss, W. J., Sharp, D. J., Eriksen, M. P., Pirkle, J. L., & Maurer, K. R. (1998). Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. The Journal of the American Medical Association, 280, 135-139.
26. Carmelli, D., Swan, G. E., Robinette, D., & Fabsitz, R. (1992). Genetic influence on smoking - A study of male twins. The New England Journal of Medicine, 327, 829-833.
27. Carson, R. A., & Rothstein, M. A. (Eds.). (1999). Behavioral genetics: The clash of culture and biology. Baltimore, MD: The Johns Hopkins University Press.
28. Celis, J. E., Kruhoffer, M., Gromova, I., Frederiksen, C., Ostergaard, M., Thykjaer, T., Gromov, P., Yu, J., Palsdottir, H., Magnusson, N., & Orntoft, T. F. (2000). Gene expression profiling: Monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Letter, 480, 2-16.
29. Chakravarti, A. (2001). ...to a future of genetic medicine. Nature, 409, 822-823.
30. Chapman, S., Wong, W. L., & Smith, W. (1993). Self-exempting beliefs about smoking and health: Differences between smokers and ex-smokers. American Journal of Public Health, 83, 215-219.
31. Cheng, L. S., Swan, G. E., & Carmelli, D. (2000). A genetic analysis of smoking behavior in family members of older adult males. Addiction, 95, 427-435.
32. Cockett, M., Dracopoli, N., & Sigal, E. (2000). Applied genomics: Integration of the technology within pharmaceutical research and development. Current Opinion in Biotechnology, 11, 602-609.
33. Cohen, S. B. (1988). Tobacco addiction as a psychiatric disease. Southern Medical Journal, 81, 1083-1088.
34. Collins, F. S., & McKusick, V. A. (2001). Implications of the Human Genome Project for medical science. The Journal of the American Medical Association, 285, 540-544.
35. Comings, D. E. (2000). Reward deficiency syndrome: Genetic aspects of behavioral disorders. Progress in Brain Research, 125, 325-341.
36. Comings, D. E., Comings, B. G., & Knell, E. (1989). Hypothesis: Homozygosity in Tourette syndrome. American Journal of Medical Genetics, 34, 413-421.
37. Comings, D. E., Comings, B. G., Muhleman, D., Dietz, G., Shahbahrami, B., Tast, D., Knell, E., Koesis, P., Baumgarten, R., & Kovacs, B. W. (1991). The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. The Journal of the American Medical Association, 266, 1793-1800.
38. Comings, D. E., Ferry, L., Bradshaw-Robinson, S., Burchette, R., Chiu, C., & Muhleman, D. (1996). The dopamine D2 receptor (DRD2) gene: A genetic risk factor in smoking. Pharmacogenetics, 6, 73-79.
39. Comings, D. E., Gade, R., Wu, S., Chiu, C., Dietz, G., Muhleman, D., Saucier, G., Ferry, L., Rosenthal, R. J., Lesieur, H. R., Rugle, L. J., & MacMurray, P. (1997). Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Molecular Psychiatry, 2, 44-56.
40. Comings, D. E., Rosenthal, R. J., Lesieur, H. R., Rugle, L. J., Muhleman, D., Chiu, C., Dietz, G., & Gade, R. (1996). A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics, 6, 223-234.
41. Comings, D. E., Wu, S., Chiu, C., Ring, R. H., Gade, R., Ahn, C., MacMurray, J. P., Dietz, G., & Mubleman, D. (1996c). Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: The additive and subtractive effect of the three dopaminergic genes - DRD2, D beta H. and DAT1. American Journal of Medical Genetics, 67, 264-288.
42. Conrad, P. (1992). Medicalization and social control. Annual Review of Sociology, 18, 209-232.
43. Conrad, P. (1999). A mirage of genes. Sociology of Health and Illness, 21, 228-239.
44. Conrad, P., & Schneider, J. W. (1980). Deviance and medicalifation: From badness to sickness. St. Louis, MO: Mosby.
45. Corrigall, W. A. (1991). Understanding brain mechanisms in nicotine reinforcement. British Journal of Addiction, 86, 507-510.
46. Covey, L. S. (1999). Tobacco cessation among patients with depression. Primary, Care, 26, 691-706.
47. Covey, L. S., Sullivan, M. A., Johnston, J. A., Glassman, A. H., Robinson, M. D., & Adams, D. P. (2000). Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs, 59, 17-31.
48. Cowan, W. M., & Kandel, E. R. (2001). Prospects for neurology and psychiatry. The Journal of the American Medical Association, 285, 594-600.
49. Crawford, R. (1985). A cultural account of "health": Control, release, and the social body. In J. B. McKinlay (Ed.), Issues in the political economy of health (pp. 60-106). New York: Methuen-Tavistock.
50. Crawford, R. (1994). The boundaries of the self and the unhealthy other: Reflections on health, culture, and AIDS. Social Science & Medicine, 38, 1347-1365.
51. Curry, S. J., Grothaus, L. C., McAfee, T., & Pabiniak, C. (1998). Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. The New England Journal of Medicine, 339, 673-679.
52. Dalton, M., Sargent, J., Beach, M., Titus-Ernstoff, L., Ginbson, J., Ahrens, M., Tickle, J. J., & Heatherton, T. F. (2003). Effect of viewing smoking in movies on adolescent smoking initiation: A cohort study. Lancet, 362, 281-285.
53. Dani, J. A., & Heinemann, S. (1996). Molecular and cellular aspects of nicotine abuse. Neuron, 16, 905-908.
54. Dewey, S. L., Brodie, J. D., Gerasimov, M., Horan, B., Gardner, E. L., & Ashby, C. R. (1999). A pharmacologic strategy for the treatment of nicotine addiction. Synapse, 31, 76-86.
55. Duga, S., Solda, G., Asselta, R., Bonati, M. T., Dalpra, L., Malcovati, M., & Tenchini, M. L. (2001). Characterization of the genomic structure of the human neuronal nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster and identification of novel intragenic polymorphisms. Journal of Human Genetics, 46, 640-648.
56. Duggirala, R., Almasy, L., & Blangero, J. (1999). Smoking behavior is under the influence of a major quantitative trait locus on human chromosome 5q. Genetic Epidemiology, 17 (Suppl. 1), S139-S144.
57. Duster, T. (1990). Backdoor to eugenics: Chapter 5: The increasing appropriation of genetic explanations. New York: Routledge.
58. Elias, M. (1999, January 25). Ability to quit smoking linked to genetic profile. USA Today, 6-D.
59. ELSI Research Planning and Evaluation Group. (2000). A review and analysis of the ELSI [ethical, legal and social implications] research programs at the National Institutes of Health and the Department of Energy. ERPEG final report. Retrieved October 27, 2004, from www.genome.gov/10001727
60. Emery, S., Gilpin, E. A., Ake, C., Farkas, A. J., & Pierce, J. P. (2000). Characterizing and identifying "hard-core" smokers: Implications for further reducing smoking prevalence. American Journal of Public Health, 90, 387-394.
61. Epstein, R. H. (1998, October 6). Overcoming the stigma of lung cancer. The Washington Post, 13.
62. Ernst, M., Heishman, S. J., Spurgeon, L., & London, E. D. (2001). Smoking history and nicotine effects on cognitive performance. Neuropsychopharmacology, 25, 313-319.
63. Etkin, A. (2000). Drugs and therapeutics in the age of the genome. The Journal of the American Medical Association, 284, 2786-2787.
64. Evans, W. E., & Relling, M. V. (1999). Pharmacogenomics: Translating functional genomics into rational therapeutics. Science, 286, 487-491.
65. Fowler J. S., Volkow N. D., Wang G. J., Pappas N., Logan J., Shea C., et al. (1996). Brain monoamine oxidase A inhibition in cigarette smokers. Proceedings of the National Academy of Sciences USA, 93, 14065-14069.
66. Gamberino, W. C., & Gold, M. S. (1999). Neurobiology of tobacco smoking and other addictive disorders. Psychiatric Clinics of North America, 22, 301-312.
67. Gault, J., Robinson, M., Berger, R., Drebing, C., Logel, J., Hopkins, J., Moore, T., Jacobs, S., Meriwether, J., Choi, M. J., Kim, E. J., Walton, K., Buiting, K., Davis, A., Breese, C., Freedman, R., & Leonard, S. (1998). Genomic organization and partial duplication of the human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics, 52, 173-185.
68. Glantz, S. A. (2003). Smoking in movies: A major problem and a real solution. Lancet, 362, 258-259.
69. Glassman, A. H., Helzer, J. E., Covey, L. S., Cottler, L. B., Stetner, F., Tipp, J. E., & Johnson, J. (1990). Smoking, smoking cessation, and major depression. The Journal of the American Medical Association, 264, 1546-1549.
70. Goffman, E. (1963). Stigma: Notes on the management of spoiled identity. Garden City, NY: Anchor.
71. Goldstein, J. (1991). The stigmatization of smokers: An empirical investigation. Journal of Drug Education, 21, 167-182.
72. Goodin, R. E. (1989). No smoking: The ethical issues. Chicago: The University of Chicago Press.
73. Grant, S., Contoreggi, C., & London, E. D. (2000). Drug abusers show impaired performance in a laboratory test of decision making. Neuropsychologia, 38, 1180-1187.
74. Greely, H. T. (1998). Legal, ethical, and social issues in human genome research. Annual Review of Anthropology, 27, 4.
75. Gusfield, J. R. (1993). The social symbolism of smoking and health. In R. L. Rabin & S. D. Sugarman (Eds.). Smoking policy: Law, politics, and culture (pp. 49-68). New York: Oxford University Press.
76. Hall, W., Carter, L., & Morley, K. (2003). Addiction, neuroscience, and ethics [editorial]. Addiction, 98, 867-870.
77. Hall, W., Madden, P., & Lynskcy, M. (2002). The genetics of tobacco use: Methods, findings and policy implications. Tobacco Control, 11, 119-124.
78. Harris, H. W., & Schaffner, K. F. (1992). Molecular genetics, reductionism, and disease concepts in psychiatry. The Journal of Medicine and Philosophy, 17, 127-153.
79. Haybron, R. (1998, March 22). A smoker who can't quit may have "smoking gene." The Plain Dealer, 8-J.
80. Heath, A. C., Kirk, K. M., Meyer, J. M., & Martin, N. G. (1999). Genetic and social determinants of initiation and age at onset of smoking in Australian twins. Behavior Genetics, 29, 395-407.
81. Heath, A. C., & Martin, N. G. (1993). Genetic models for the natural history of smoking: Evidence for a genetic influence on smoking persistence. Addictive Behaviors, 18, 19-34.
82. Heinz, A., Goldman, D., Jones, D. W., Palmour, R., Hommer, D., Gorey, J. G., Lee, K. S., Linnoila, M., & Weinberger, D. R. (2000). Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology, 22, 133-139.
83. Heishman, S. J. (1999). Behavioral and cognitive effects of smoking: Relationship to nicotine addiction. Nicotine & Tobacco Research, 1 (Suppl. 2), S143-S147; discussion, S165-S146.
84. Heishman, S. J., Kozlowski, L. T., & Henningfield, J. E. (1997). Nicotine addiction: Implications for public health policy. Journal of Social Issues, 53, 13-33.
85. Holtzman, N. A., & Marteau, T. M. (2000). Will genetics revolutionize medicine? The New England Journal of Medicine, 343, 141-144.
86. Hu, S., Brody, C. L., Fisher, C., Gunzerath, L., Nelson, M. L., Sabol, S. Z., Sirota, L. A., Marcus, S. E., Greenberg, B. D., Murphy, D. L., & Hamer, D. H. (2000). Interaction between the serotonin transporter gene and neuroticism in cigarette smoking behavior. Molecular Psychiatry, 5, 181-188.
87. Hughes, J. R. (1986). Genetics of smoking: A brief review. Behavior Therapy, 17, 335-345.
88. Hyman, S. E. (2000). The millennium of mind, brain and behavior. Archives of General Psychiatry, 57, 88-89.
89. Issa, A. M., & Keyserlingk, E. W. (2000). Apolipoprotein E genotyping for pharmacogenctic purposes in Alzheimer's disease: Emerging ethical issues. Canadian Journal of Psychiatry, 45, 917-922.
90. Jentsch, J. D., & Taylor, J. R. (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: Implications for the control of behavior by reward-related stimuli. Psychopharmacology, 146, 373-390.
91. Johnson, B. A., & Ait-Daoud, M. (1999). Medications to treat alcoholism. Alcohol Research & Health, 23, 99-106.
92. Johnson, B. A., Roache, J. D., Javors, M. A., DiClemente, C. C., Cloninger, C. R., Prihoda, T. J., Bordnick, P. S., Ait-Daoud, N., & Hensler, J. (2000). Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. The Journal of the American Medical Association, 284, 963-971.
93. Jorm, A. F., Henderson, A. S., Jacomb, P. A., Christensen, H., Korten, A. E., Rodgers, B., Tan, X., & Easteal, S. (2000). Association of smoking and personality with a polymorphism of the dopamine transporter gene: Results from a community survey. American Journal of Medical Genetics, 96, 331-334.
94. Kaplan, J. M. (2000). The limits and lies of human genetic research: Dangers for social Policy. New York: Routledge.
95. Katz, S. (1997). Secular morality. In A. M. Brandt & P. Rozin (Eds.), Morality and health (pp. 297-330). New York: Routledge.
96. Kaufert, P. A. (2000). Health policy and the new genetics. Social Science & Medicine, 51, 821-829.
97. Kendler, K. S., Thornton, L. M., & Pederson, N. L. (2000). Tobacco consumption in Swedish twins reared apart and reared together. Archives of General Psychiatry, 57, 886-892.
98. Kessler, D. A. (1995). Nicotine addiction in young people. The New England Journal of Medicine, 333, 186-189.
99. Kessler, D. A., Barnett, P. S., Witt, A., Zeller, M. R., Mande, J. R., & Schultz, W. B. (1997). The legal and scientific basis for FDA's assertion of jurisdiction over cigarettes and smokeless tobacco. The Journal of the American Medical Association, 277, 405-409.
100. Koenig, B. A., Greely, H. T., McConnell, L. M., Silverberg, H. L., & Raffin, T. (1998). Genetic testing for BRCA1 and BRCA2: Recommendations of the Stanford Program in Genomics. Ethics and Society. Journal of Women's Health, 7, 531-545.
101. Koob, G. F. (1996). Drug addiction: The yin and yang of hedonic homeostasis. Neuron, 16, 893-896.
102. Koopmans, J. R., Slutske, W. S., Heath, A. C., Neale, M. C., & Boomsma, D. I. (1999). The genetics of smoking initiation and quantity smoked in Dutch adolescent and young adult twins. Behavior Genetics, 29, 383-393.
103. Kosten,T. R. (1998). Addiction as a brain disease. American Journal of Psychiatry, 155, 711-713.
104. Lander, E. S. (2000). Genomics: Launching a revolution in medicine. The Journal of Law, Medicine & Ethics, 28 (Special suppl.), 3-14.
105. Landrine, H., & Klonoff, E. A. (2000). Racial discrimination and cigarette smoking among Blacks: findings from two studies. Ethnicity & Disease, 10, 195-202.
106. Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D., & Bor, D. H. (2000). Smoking and mental illness. A population-based prevalence study. The Journal of the American Medical Association, 284, 2606-2610.
107. Leboyer, M., Bellivier, F., Nosten-Bertrand, M., Jouvent, R., Pauls, D., & Mallet, J. (1998). Psychiatric genetics: Search for phenotypes. Trends in Neuroscience, 21, 102-105.
108. Leichter, H. (1981). Voluntary health risks and public policy. 2. Public policy and the British experience. Hastings Center Report, 11, 32-39.
109. Leichter, H. M. (1997). Lifestyle correctness and the new secular morality. In A. M. Brandt & P. Rozin (Eds.), Morality and health (pp. 359-378). New York: Routledge.
110. Lerman, C., Caporaso, N. E., Audrain, J., Main, D., Bowman, E. D., Lockshin, B., Boyd, N. R., & Shields, P. G. (1999). Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychology, 18, 14-20.
111. Lerman, C., Caporaso, N. E., Audrain, J., Main, D., Boyd, N. R., & Shields, P. G. (2000). Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Molecular Psychiatry, 5, 189-192.
112. Lerman, C., Caporaso, N. E., Bush, A., Zheng, Y. L., Audrain, J., Main, D., & Shields, P. G. (2001). Tryptophan hydroxylase gene variant and smoking behavior. American Journal of Medical Genetics, 105, 518-520.
113. Lerman, C., Caporaso, N., Main, D., Audrain, J., Boyd, N. R., Bowman, E. D., & Shields, P. G. (1998). Depression and self-medication with nicotine: The modifying influence of the dopamine D4 receptor gene. Health Psychology, 17, 56-62.
114. Lerman, C., & Niaura, R. (2002). Applying genetic approaches to the treatment of nicotine dependence. Oncogene, 21, 7412-7420.
115. Lerman, C., Shields, P. G., Audrain, J., Main, D., Cobb, B., Boyd, N. R., & Caporaso, N. (1998). The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiology, Biomarkers & Prevention, 7, 253-255.
116. Lerman, C. & Swan, G. E. (2002). Non-replication of genetic association studies: Is DAT all, folks? Nicotine & Tobacco Research, 4, 247-249.
117. Leshner, A. I. (1997). Addiction is a brain disease, and it matters. Science, 278, 450-457.
118. Leshner, A. I. (1999). Science-based views of drug addiction and its treatment. The Journal of the American Medical Association, 282, 1314-1316.
119. Levenson, J., & Olbrisch, M. (1993). Psychosocial evaluation of organ transplant candidates. A comparative survey of process, criteria, and outcome in heart, liver, and kidney transplantation. Psychosomatics, 34, 314-323.
120. Levin, B., & Fleischman, A. (2002). Public health and bioethics: The benefits of collaboration. American Journal of Public Health, 92, 165-167.
121. Lewohl, J. M., Wang, L., Miles, M. F., Zhang, L., Dodd, P. R., & Harris, R. A. (2000). Gene expression in human alcoholism: Microarray analysis of frontal cortex. Alcoholism Clinical and Experimental Research, 24, 1873-1882.
122. Lewontin, R. C., Rose, S. P., & Kamin, L. J. (1984). Not in our genes: Biology, ideology, and human nature. New York: Pantheon.
123. Lippman, A. (1992). Led (astray) by genetic maps: The cartography of the human genome and health care. Social Science & Medicine, 35, 1469-1476.
124. London, E. D., Ernst, M., Grant, S., Bonson, K., & Weinstein, A. (2000). Orbitofrontal cortex and human drug abuse: Functional imaging. Cerebral Cortex, 10, 334-342.
125. London, S. J., Idle, J. R., Daly, A. K., & Coetzec, G. A. (1999). Genetic variation of CYP2A6, smoking, and risk of cancer [letter]. Lancet, 353, 898-899.
126. Loriot, M. A., Rebuisson, S., Oscarson, M., Cenee, S., Miyamoto, M., Ariyoshi, N., Kamataki, T., Hemon, D., Beaune, P., & Stucker, I. (2061). Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics, 11, 39-44.
127. Lupton, D. (1993). Risk as moral danger: The social and political functions of risk discourse in public health. International Journal of Health Services, 23, 425-435.
128. Lyvers, M. (2000). "Loss of control" in alcoholism and drug addiction: A neuroscientific interpretation. Experimental and Clinical Psychopharmacology, 8, 225-249.
129. Maldonado, R., Saiardi, A., Valverde, O., Samad, T., Roques, B. P., & Borrelli, E. (1997). Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature, 388, 586-589.
130. Markle, G. E., & Troyer, R. J. (1979). Smoke gets in your eyes: Cigarette-smoking as deviant-behavior. Social Problems, 26, 611-625.
131. Marshall, S., Kramer, M., Lewiston, N., Starnes, V., & Theodore, J. (1990). Selection and evaluation of recipients for heart-lung and lung transplantation. Chest, 98, 1488-1494.
132. Marteau, T. M., & Senior, V. (1997). Illness representations after the Human Genome Project: The perceived role of genes in causing illness. In K. J. Petri & J. A. Weinman (Eds.), Perceptions of heallh and illness: Current research and applications (pp. 241-266). Amsterdam: Harwood Academic.
133. Martinez, D., Gelernter, J., Abi-Dargham, A., van Dyck, C. H., Kegeles, L., Innis, R. B., & Laruelle, M. (2001). The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology, 24, 553-560.
134. McConnell, L. M., Koenig, B. A., Greely, H. T., & Raffin, T. A. (1999). Genetic testing and Alzheimer disease: Recommendations of the Stanford Program in Genomics, Ethics, and Society. Genetic Testing, 3, 3-12.
135. McEwen, A., & West, R. (2001). Smoking cessation activities by general practitioners and practice nurses. Tobacco Control, 10, 27-32.
136. McGuffin, P., Riley, B., & Plomin, R. (2001). Toward behavioral genomics. Science, 291, 1232-1249.
137. McKinney, E. F., Walton, R. T., Yudkin, P., Fuller, A., Haldar, N. A., Mant, D., Murphy, M., Welsh, K. I., & Marshall, S. E. (2000). Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics, 10, 483-491.
138. Miller, L. W., Kubo, S. H., Young, J. B., Stevenson, L. W., Loh, E., & Costanzo, M. R. (1995). Report of the consensus conference on candidate selection for heart transplantation-1993. The Journal of Heart and Lung Transplantation, 14, 562-571.
139. Miller, N. S., Guttman, J. C., & Chawla, S. (1997). Integration of generalized vulnerability to drug and alcohol addiction. Journal of Addictive Diseases, 16, 7-22.
140. Murray, R. F., Jr. (1996). The Human Genome Project: Its impact on medical practice. In T. H. Murray, M. A. Rothstein, & R. F. Murray Jr. (Eds.), The Human Genome Project and the future of health care (pp. 196-208). Bloomington: Indiana University Press.
141. Nathanson, C. A. (1999). Social movements as catalysts for policy change: The case of smoking and guns. Journal of Health Politics, Policy and Law, 24, 421-488.
142. Nelkin, D., & Lindee, M. S. (1995). The DNA mystique: The gene as a cultural icon. New York: Freeman.
143. Nestler, E., & Landsman, D. (2001). Learning about addiction from the genome. Nature, 409, 834-835.
144. Noble, E. P. (2000). Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: A review. European Psychiatry, 15, 79-89.
145. Noble, E. P., Berman, S. M., Ozkaragoz, T. Z., & Ritchie, T. (1994). Prolonged P300 latency in children with the D2 dopamine receptor A1 allele. American Journal of Human Genetics, 54, 658-668.
146. Noble, E. P., Blum, K., Khalsa, M. E., Ritchie, T., Montgomery, A., Wood, R. C., Fitch, R. J., Ozkaragoz, T., Sheridan, P. J., & Anglin, M. D. (1993). Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug and Alcohol Dependence, 33, 271-285.
147. Noble, E. P., Blum, K., Ritchie, T., Montgomery, A., & Sheridan, P. J. (1991). Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Archives of General Psychiatry, 48, 648-654.
148. Noble, E. P., Noble, R. E., & Ritchie, T. (1994). D2 dopamine receptor gene and obesity. Journal of Eating Disorders, 15, 205-217.
149. Noble, E. P., St. Jeor, S. T., Ritchie, T., Syndulko, K., St. Jeor, S. C., Fitch, R. J., Brunner, R. L., & Sparkes, R. S. (1994). D2 dopamine receptor gene and cigarette smoking: A reward gene? Medical Hypotheses, 42, 257-260.
150. Noble, E. P., Zhang, X., Ritchie, T. L., & Sparkes, R. S. (2000). Haplotypes at the DRD2 locus and severe alcoholism. American Journal of Medical Genetics, 96, 622-631.
151. Nuffield Council on Bioethics. (2002). Genetics and human behaviour: The ethical context. London: Author.
152. Oscarson, M., Gullsten, H., Rautio, A., Bernal, M., Sinues, B., Dahl, M.-L., Stengard, J. H., Pelkonen, O., Raunio, H., & Ingelman-Sundberg, M. (1998). Genotyping of human cytochrome P450 2A6 (CYP2A6). a nicotine C-oxidase. FEBS Letter, 438, 201-205.
153. Owen, M. J., Cardno, A. G., & O'Donovan, M. C. (2000). Psychiatric genetics: Back to the future. Molecular Psychiatry, 5, 22-31.
154. Parens, E. (1996). Taking behavioral genetics seriously. Hastings Center Report, 26, 13-18.
155. Parens, E. (2004). Genetic differences and human identities: On why talking about behavioral genetics is important and difficult. Hastings Center Report, 34 (1 Suppl. 1), S1-S35.
156. Parker, L. S. (1995). Ethical concerns in the research and treatment of complex disease. Trendy in Genetics, 11, 520-523.
157. Parker, L. S. (1999). Genetics, social responsibility, and social practices. In J. R. Botkin W. M. McMahon, & L. P. Francis (Eds.), Genetics and criminality: The potential misuse of scientific information in court (pp. 76-81). Washington, DC: American Psychological Association.
158. Peltonen, L., & McKusick, V. A. (2001). Dissecting human disease in the postgenomic era. Science, 291, 1224-1229.
159. Pérez-Stable, E. J., Herrera, B., Jacob, P., & Benowitz, N. L. (1998). Nicotine metabolism and intake in Black and White smokers. The Journal of the American Medical Association, 280, 152-156.
160. Perry, D. C., Davila-Garcia, M. I., Stockmeier, C. A., & Kellar, K. J. (1999). Increased nicotinic receptors in brains from smokers: Membrane binding and autoradiography studies. The Journal of Pharmacology and Experimental Therapeutics, 289, 1545-1552.
161. Pianezza, M. L., Sellers, E. M., & Tyndale, R. F. (1998). Nicotine metabolism defect reduces smoking. Nature, 393, 750.
162. Pich, E. M., Chiamulera, C., & Tessari, M. (1998). Neural substrate of nicotine addiction as defined by functional brain maps of gene expression. Journal of Physiology, Paris, 92, 225-228.
163. Pidoplichko, V. I., DeBiasi, M., Williams, J. T., & Dani, J. A. (1997). Nicotine activates and desensitizes midbrain dopamine neurons. Nature, 390, 401-404.
164. Pomerleau, O. F. (1995). Individual differences in sensitivity to nicotine: Implications for genetic research on nicotine dependence. Behavior Genetics, 25, 161-177.
165. Pontieri, F. E., Tanda, G., Orzi, F., & Di Chiara, G. (1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 382, 255-257.
166. Quattrocki, E., Baird, A., & Yurgelun-Todd, D. (2000). Biological aspects of the link between smoking and depression. Harvard Review of Psychiatry, 8, 99-110.
167. Rapp, R. (1988). Chromosome and communication: The discourse of genetic counseling. Medical Anthropology Quarterly, 2, 143-157.
168. Ritter, M. (1998, June 25). Study links gene to nicotine habit; May provide hope for stop-smoking drug. Chicago Sun-Times, 36,
169. Ritter, M. (1999, January 25). Gene may influence smoking. The Buffalo News, 4-A.
170. Rogers, R. D., & Robbins, T. W. (2001). Investigating the neurocognitive deficits associated with chronic drug misuse. Current Opinions in Neurobiology, 11, 250-257.
171. Roses, A. D. (2000). Pharmacogenetics and the practice of medicine. Nature, 405, 857-865.
172. Rothenberg, K. H. (1997). Breast cancer, the genetic "quick fix," and the Jewish community. Ethical, legal, and social challenges. Health Matrix, 7, 97-124.
173. Rothstein, M. A., & Epps, P. G. (2001). Ethical and legal implications of pharmacogenomics. Nature Review Genetics, 2, 228-231.
174. Rowe, D. C., & Jacobson, K. C. (1999). In the mainstream: Research in behavioral genetics. In R. A. Carson & M. A. Rothstein (Eds.), Behavioral genetics: The Clash of biology and culture (pp. 12-34). Baltimore, MD: The Johns Hopkins University Press.
175. Rudert, F. (2000). Genomics and proteomics tools for the clinic. Current Opinions in Molecular Therapeutics, 2, 633-642.
176. Rusnak, J. M., Kisabeth, R. M., Herbert, D. P., & McNeil, D. M. (2001). Pharmacogenomics: A clinician's primer on emerging technologies for improved patient care. Mayo Clinic Proceedings, 76, 299-309.
177. Sabol, S. Z., Nelson, M. L., Fisher, C., Gunzerath, L., Brody, C. L., Hu, S., Sirota, L. A., Marcus, S. E., Greenberg, B. D., Lucas, F. R. 4th, Benjamin, J., Murphy, D. L., & Hamer, D. H. (1999). A genetic association for cigarette smoking behavior. Health Psychology, 18, 7-13.
178. Sachs, L. (1996). Causality, responsibility and blame - core issues in the cultural construction and subtext of prevention. Sociology of Health and Illness, 18, 632-652.
179. Sander, C. (2000). Genomic medicine and the future of health care. Science, 287, 1977-1978.
180. Schork, N. J., Fallin, D., Thiel, B., Xu, X., Broeckel, U., Jacob, H. J., & Cohen, D. (2001). The future of genetic case-control studies. Advances in Genetics, 42, 191-212.
181. Sellers, E. M. (1998). Pharmacogenetics and ethnoracial differences in smoking. The Journal of the American Medical Association, 280, 179-180.
182. Sellers, E. M., Kaplan, H. L., & Tyndale, R. F. (2000). Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology and Therapeutics, 68, 35-43.
183. Sellers, E. M., & Tyndale, R. F. (2000). Mimicking gene defects to treat drug dependence. Annals of the New York Academy of Sciences, 909, 233-246.
184. Sher, L. (2000). Psychiatric diagnoses and inconsistent results of association studies in behavioral genetics. Medical Hypotheses, 54, 207-209.
185. Shields, P. G., Lerman, C., Audrain, J., Bowman, E. D., Main, D., Boyd, N. R., & Caporaso, N. E. (1998). Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiology, Biomarkers & Prevention, 7, 453-458.
186. Shuster, E. (1992). Determinism and reductionism: A greater threat because of the Human Genome Project? In G. J. Annas & S. Elias (Eds.), Gene mapping: Using law and ethics as guides (pp. 115-127). New York: Oxford University Press.
187. Silagy, C., & Formica, N. (2001). Place of bupropion in smoking-cessation therapy. Lancet, 357, 1550.
188. Silverman, M. A., Neale, M. C., Sullivan, P. F., Harris-Kerr, C., Wormley, B., Sadek, H., Ma, Y., Kendler, K. S., & Straub, R. E. (2000). Haplotypes of four novel single nucleotide polymorphisms in the nicotinic acetylcholine receptor beta2-subunit (CHRNB2) gene show no association with smoking initiation or nicotine dependence. American Journal of Medical Genetics, 96, 646-653.
189. Slade, J. (1999). Cessation: It's time to retire the term. Retrieved October 12. 1999, from http://www.srnt.org/publications/newsltr/SRNT
190. Slotkin, T. A., Pinkerton, K. E., Auman, J. T., Qiao, D., & Seidler, F. J. (2002). Perinatal exposure to environmental tobacco smoke upregulates nicotinic cholinergic receptors in monkey brain. Brain Research. Developmental Brain Research, 133, 175-179.
191. Smith, S. S., O'Hara, B. F., Persico, A. M., Gorelick, D. A., Newlin, D. B., Vlahov, D., Solomon, L., Pickens, R., & Uhl, G. R. (1992). Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. Archives of General Psychiatry, 49, 723-727.
192. Smoking cessation services: Coverage and utilization. (1999). Managed Care Interface, 12, 81-82.
193. Spitz, M. R., Shi, H., Yang, F., Hudmon, K. S., Jiang, H., Chamberlain, R. M., Amos, C. I., Wan, Y., Cinciripini, P., Hong, W. K., & Wu, X. (1998). A case-control study of the dopamine D2 receptor gene and smoking status in lung cancer. Journal of the National Cancer Institute, 90, 358-363.
194. Stallings, M. C., Hewitt, J. K., Beresford, T., Heath, A. C., & Eaves, L. J. (1999). A twin study of drinking and smoking onset and latencies from first use to regular use. Behavior Genetics, 29, 409-421.
195. Steinberg, J., & White, R. (1996). The advantages of the disease model. MSDA Journal, 39, 87-88.
196. Stolerman, I. P., & Shoaib, M. (1991). The neurobiology of tobacco addiction. Trendy in Pharmacological Sciences, 12, 467-473.
197. Stoltenberg, S. F., & Burmeister, M. (2000). Recent progress in psychiatric genetics - some hope but no hype. Human Molecular Genetics, 9, 927-935.
198. Straub, R. E., Sullivan, P. F., Ma, Y., Myakishev, M. V., Harris-Kerr, C., Wormley, B., Kadambi, B., Sadek, H., Silverman, M. A., Webb, B. T., Neale, M. C., Bulik, C. M., Joyce, P. R., & Kendler, K. S. (1999). Susceptibility genes for nicotine dependence: A genome scan and followup in an independent sample suggest that regions on chromosomes 2, 4, 10, 16, 17 and 18 merit further study. Molecular Psychiatry, 4, 129-144.
199. Sullivan, P. F., Jiang, Y., Neale, M. C., Kendler, K. S., & Straub, R. E. (2001). Association of the tryptophan hydroxylase gene with smoking initiation but not progression to nicotine dependence. American Journal of Medical Genetics, 105, 479-484.
200. Sullivan, P. F., Neale, M. C., Silverman, M. A., Harris-Kerr, C., Myakishev, M. V., Wormley, B., Webb, B. T., Ma, Y., Kendler, K. S., & Straub, R. E. (2001). An association study of DRD5 with smoking initiation and progression to nicotine dependence. American Journal of Medical Genetics, 105, 259-265.
201. Swan, G. E., Carmelli, D., & Cardon, L. R. (1997). Heavy consumption of cigarettes, alcohol and coffee in male twins. Journal of Studies on Alcohol, 58, 182-190.
202. Swan, G. E., & Lessov, C. (2004). Gene-environment interaction in nicotine addiction: The need for a large-scale, collaborative effort. Substance Use and Misuse, 39, 2083-2085.
203. Tesh, S. (1981). Disease causality and politics. Journal of Health Politics, Policy and Law, 6, 369-390.
204. Thibault, C., Lai, C., Wilke, N., Duong, B., Olive, M. F., Rahman, S., Dong, H., Hodge, C. W., Lockhart, D. J., & Miles, M. F. (2000). Expression profiling of neural cells reveals specific patterns of ethanol-responsive gene expression. Molecular Pharmacology, 58, 1593-1600.
205. Thorndike, A. N., Rigotti, N. A., Stafford, R. S., & Singer, D. E. (1998). National patterns in the treatment of smokers by physicians. The Journal of the American Medical Association, 279, 604-608.
206. Tiihonen, J., Pesonen, U., Kauhanen, J., Koulu, M., Hallikainen, T., Leskinen, L., & Salonen, J. T. (2000). CYP2A6 genotype and smoking [letter]. Molecular Psychiatry, 5, 347-348.
207. Torres, G., & Horowitz, J. M. (1999). Drugs of abuse and brain gene expression. Psychosomatic Medicine, 61, 630-650.
208. Trauth, J. A., Seidler, F. J., & Slotkin, T. A. (2000). An animal model of adolescent nicotine exposure: Effects on gene expression and macromolecular constituents in rat brain regions. Brain Research, 7, 29-39.
209. True, W. R., Heath, A. C., Scherrer, J. F., Waterman, B., Goldberg, J., Lin, N., Eisen, S. A., Lyons, M. J., & Tsuang, M. T. (1997). Genetic and environmental contributions to smoking. Addiction, 92, 1277-1287.
210. Uhl, G., Blum, K., Noble, E. P., & Smith, S. (1993). Substance abuse vulnerability and D2 receptor genes. Trends in Neuroscience, 16, 83-88.
211. U.S. Department of Health and Human Services. (1988). The health consequences of smoking: Nicotine addiction. A report of the surgeon general. Washington, DC: U.S. Government Printing Office.
212. U.S. Department of Health and Human Services. (2000). Reducing tobacco use. A report of the surgeon general - 2000. Atlanta, GA: Author, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
213. S. Department of Health, Education, and Welfare. (1964). Smoking and health. Report of the advisory committee to the surgeon general of the Public Health Service. Washington, D.C.: U.S. Public Health Service, Author.
214. Vandenbergh, D. J., Bennett, C. J., Grant, M. D., Strasser, A. A., O'Connor, R., Stauffer, R. L., Vogler, G. P., & Kozlowski, L. T. (2002). Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: Failure to replicate and finding that never-smokers may be different. Nicotine & Tobacco Research, 4, 333-340.
215. Veenstra-VanderWeele, J., Anderson, G. M., & Cook, E. H. J. (2000). Pharmacogenetics and serotonin system: Initial studies and future directions. European Journal of Pharmacology, 410, 165-181.
216. Volkow, N. D., & Fowler, J. S. (2000). Addiction, a disease of compulsion and drive: Involvement of the orbitofrontal cortex. Cerebral Cortex, 10, 318-325.
217. Waldman, I. D., & Slutske, W. S. (2000). Antisocial behavior and alcoholism: A behavioral genetic perspective on comorbidity. Clinical Psychology Review, 20, 255-287.
218. Warner, K. E., & Burns, D. M. (2003). Hardening and the hard-core smoker: Concepts, evidence, and implications. Nicotine & Tobacco Research, 5, 37-48.
219. Warner, K. E., Slade, J., & Sweanor, D. T. (1997). The emerging market for long-term nicotine maintenance. The Journal of the American Medical Association, 278, 1087-1092.
220. Williams, S. J. (1998). Health as moral performance: Ritual, transgression and taboo. Health, 2, 435-457.
221. Wise, R. A. (2000). Addiction becomes a brain disease. Neuron, 26, 27-33.
222. Wong, A. H., Buckle, C. E., & Van Tol, H. H. (2000). Polymorphisms in dopamine receptors: What do they tell us? European Journal of Pharmacology, 410, 183-203.
223. Woolf, A. D. (1997). Smoking and nicotine addiction: A pediatric epidemic with sequelae in adulthood. Current Opinions in Pediatrics, 9, 470-477.
224. World Health Organization. (1992). International statistical classification of diseases and related health problems (10th ed.), Geneva, Switzerland: Author.
225. Zola, I. K. (1972). Medicine as an institution of social control. Sociological Review, 20, 487-504.